KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Halozyme Therapeutics (HALO) over the last 14 years, with Q3 2025 value amounting to $3.0.

  • Halozyme Therapeutics' Debt to Equity fell 976.85% to $3.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0, marking a year-over-year decrease of 976.85%. This contributed to the annual value of $4.14 for FY2024, which is 7686.39% down from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Debt to Equity is $3.0, which was down 976.85% from $4.54 recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Debt to Equity registered a high of $22.69 during Q1 2023, and its lowest value of $0.32 during Q3 2021.
  • Over the past 5 years, Halozyme Therapeutics' median Debt to Equity value was $4.45 (recorded in 2021), while the average stood at $6.32.
  • In the last 5 years, Halozyme Therapeutics' Debt to Equity soared by 649568.38% in 2023 and then plummeted by 7686.39% in 2024.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Debt to Equity stood at $4.45 in 2021, then soared by 99.27% to $8.87 in 2022, then soared by 101.68% to $17.89 in 2023, then crashed by 76.86% to $4.14 in 2024, then dropped by 27.56% to $3.0 in 2025.
  • Its last three reported values are $3.0 in Q3 2025, $4.54 for Q2 2025, and $3.13 during Q1 2025.